-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 22, Xintian Pharmaceutical issued an announcement stating that Huilun Jiangsu Pharmaceutical, a wholly-owned subsidiary of its shareholding company Huilun Biotechnology, had recently received the "Drug Registration Certificate" for temozolomide for injection approved and issued by the State Drug Administration ( Batch number: 2021S00983)
Temozolomide is a new type of alkylating agent anti-tumor drug, which is mainly used for the treatment of glioma.
Compared with temozolomide in oral capsules, temozolomide for injection can provide medication for patients who need chemotherapy but inconvenient oral medication and have difficulty swallowing, and reduce the insufficiency of drug absorption due to vomiting of temozolomide in oral capsules, which affects the therapeutic effect